Point-of-care device manufacturer Abaxis and biosensor firm LamdaGen said this week that they have entered into an R&D agreement aiming to integrate LamdaGen's plasmonic ELISA technology on Abaxis's rotor-based POC platforms.
If the integration proves viable, the agreement would enable Abaxis to multiplex a variety of markers on its rotor-based system, Abaxis CEO Clint Severson said in a statement.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
